<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2023.1210319</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Characterization of an <italic>Enterococcus faecalis</italic> bacteriophage SFQ1 as a potential therapeutic agent</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Song</surname> <given-names>Fuqiang</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Sheng</surname> <given-names>Jun</given-names></name><xref rid="aff2" ref-type="aff"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Tan</surname> <given-names>Jishan</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author"><name><surname>Xie</surname> <given-names>Huajie</given-names></name><xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname> <given-names>Xiaoyu</given-names></name><xref rid="aff3" ref-type="aff"><sup>3</sup></xref><xref rid="c001" ref-type="corresp"><sup>&#x002A;</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Guo</surname> <given-names>Wenqiong</given-names></name><xref rid="aff4" ref-type="aff"><sup>4</sup></xref><xref rid="c002" ref-type="corresp"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2236979/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Medical Laboratory, The General Hospital of Western Theater Command</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Orthopaedics, The General Hospital of Western Theater Command</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Clinical Pharmacy, The General Hospital of Western Theater Command</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>School of Nursing, Chengdu Medical College</institution>, <addr-line>Chengdu</addr-line>, <country>China</country></aff>
<author-notes>
<fn id="fn0001" fn-type="edited-by">
<p>Edited by: Bing Liu, Xi&#x2019;an Jiaotong University, China</p>
</fn>
<fn id="fn0002" fn-type="edited-by">
<p>Reviewed by: Mengzhe Li, Beijing University of Chemical Technology, China; Mengjun Cheng, Fudan University, China</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Xiaoyu Wang, <email>scncwxy@163.com</email></corresp>
<corresp id="c002">Wenqiong Guo, <email>29980872@qq.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1210319</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>07</day>
<month>06</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Song, Sheng, Tan, Xie, Wang and Guo.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Song, Sheng, Tan, Xie, Wang and Guo</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p><italic>Enterococcus faecalis</italic> is a well-established resident of the human gastrointestinal tract and is also a major cause of human infections. Unfortunately, therapeutic options for <italic>E. faecalis</italic> infections remain limited, particularly with the emergence of vancomycin-resistant strains in hospital settings. Consequently, there has been a renewed interest in phage therapy as an alternative to antibiotics. In this study, we have isolated a bacteriophage, vB_EfaS-SFQ1, from hospital sewage, which effectively infects <italic>E. faecalis</italic> strain EFS01. Phage SFQ1 is a siphovirus and exhibits a relatively broad host range. Furthermore, it has a short latent period of approximately 10&#x2009;min and a large burst size of about 110 PFU/cell at a multiplicity of infection (MOI) of 0.01, and it could effectively disrupt the biofilms formed by <italic>E. faecalis</italic>. Thus, this study provides a detailed characterization of <italic>E. faecalis</italic> phage SFQ1, which has great potential for treating <italic>E. faecalis</italic> infections.</p>
</abstract>
<kwd-group>
<kwd>bacteriophage</kwd>
<kwd>
<italic>Enterococcus faecalis</italic>
</kwd>
<kwd>antibiotic resistance</kwd>
<kwd>phage therapy</kwd>
<kwd>vancomycin-resistant</kwd>
</kwd-group>
<contract-num rid="cn1">2023NSFSC1902</contract-num>
<contract-sponsor id="cn1">Sichuan Natural Science Foundation Project</contract-sponsor>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="34"/>
<page-count count="10"/>
<word-count count="5032"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Phage Biology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro">
<title>Introduction</title>
<p><italic>Enterococci</italic> are a group of low-GC Gram-positive cocci that comprise up to 60 different species (<xref ref-type="bibr" rid="ref8">Cattoir, 2022</xref>). Among these species, <italic>Enterococcus faecalis</italic> and <italic>Enterococcus faecium</italic> are the two main species that have become a leading cause of human infections (<xref ref-type="bibr" rid="ref20">Jabbari Shiadeh et al., 2019</xref>; <xref ref-type="bibr" rid="ref6">Bright et al., 2020</xref>; <xref ref-type="bibr" rid="ref22">Kakoullis et al., 2021</xref>). In recent years, the rise of vancomycin-resistant <italic>Enterococcus</italic> (VRE) has become a growing threat in hospital settings, and <italic>E. faecalis</italic> is the second most commonly isolated VRE species (<xref ref-type="bibr" rid="ref3">Arias et al., 2011</xref>; <xref ref-type="bibr" rid="ref19">Hayakawa et al., 2013</xref>). Moreover, <italic>E. faecalis</italic> could form biofilms that exist in the medical equipment, which makes the antibiotics ineffective against the bacteria in the biofilms (<xref ref-type="bibr" rid="ref34">Venkateswaran et al., 2022</xref>). And the formation of biofilms makes it more difficult to cure infections (<xref ref-type="bibr" rid="ref1">Ali and Neelakantan, 2022</xref>). Currently, the development of new antibacterial drugs is slow (<xref ref-type="bibr" rid="ref32">Theuretzbacher et al., 2020</xref>). Consequently, there is an urgent need for novel therapeutic agents to combat multidrug-resistant bacterial infections (<xref ref-type="bibr" rid="ref17">Gorski et al., 2016</xref>).</p>
<p>Phages, which are viruses that predate bacteria, can infect antibiotic-resistant bacteria, making them an attractive option for treating infections caused by multidrug-resistant bacteria (<xref ref-type="bibr" rid="ref10">Dion et al., 2020</xref>; <xref ref-type="bibr" rid="ref31">Strathdee et al., 2023</xref>). Phage therapy has already been successfully applied in various countries worldwide, including Belgium, Georgia, China, Germany, and the USA (<xref ref-type="bibr" rid="ref21">Jault et al., 2018</xref>; <xref ref-type="bibr" rid="ref5">Bao et al., 2020</xref>; <xref ref-type="bibr" rid="ref15">Gelman et al., 2021</xref>; <xref ref-type="bibr" rid="ref24">Leitner et al., 2021</xref>; <xref ref-type="bibr" rid="ref33">Uyttebroek et al., 2022</xref>). Several clinical trials have been conducted to evaluate the safety and efficacy of phage therapy for various bacterial infections, including <italic>Pseudomonas aeruginosa</italic> infections in cystic fibrosis patients and <italic>Staphylococcus aureus</italic> infections in diabetic foot ulcers (<xref ref-type="bibr" rid="ref28">Pires et al., 2020</xref>; <xref ref-type="bibr" rid="ref13">Egido et al., 2021</xref>; <xref ref-type="bibr" rid="ref33">Uyttebroek et al., 2022</xref>). While these studies have shown promising results, larger trials are needed to establish the safety and efficacy of phage therapy in a wider range of patients. On the other hand, more basic research is also needed to support clinical transitional research.</p>
<p>One of the key challenges facing phage therapy is the isolation of suitable phages for therapeutic use (<xref ref-type="bibr" rid="ref25">Luong et al., 2020</xref>). The failure to isolate appropriate phages is common and can hinder rapid progress in phage therapy (<xref ref-type="bibr" rid="ref29">Pires et al., 2015</xref>; <xref ref-type="bibr" rid="ref21">Jault et al., 2018</xref>). Thus, isolation and characterization of phages are needed to perform phage therapy. In this study, we isolated a new lytic phage named vB_EfaS-SFQ1 from hospital sewage. Phage SFQ1 is a siphovirus and exhibits a relatively broad host range against <italic>E. faecalis</italic>, although it could not infect <italic>E. faecium</italic>. We provided a detailed biological and genomic description of phage SFQ1 and demonstrated its potential as a candidate for phage-based therapy against <italic>E. faecalis</italic> infections <italic>in vitro</italic>. Our findings contribute to the ongoing efforts to develop effective and safe phage-based therapies to combat multidrug-resistant bacterial infections.</p>
</sec>
<sec id="sec2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="sec3">
<title>Strains and cultural conditions</title>
<p>Clinical strains of <italic>E. faecalis</italic> were isolated from the Department of Clinical Laboratory Medicine and subsequently preserved in our laboratory. To culture <italic>E. faecalis</italic>, brain heart infusion (BHI) medium was utilized and incubated aerobically with shaking at 37&#x00B0;C.</p>
</sec>
<sec id="sec4">
<title>Isolation of phage that infects <italic>Enterococcus faecalis</italic></title>
<p>The bacteriophage was isolated from hospital sewage using the previously described method (<xref ref-type="bibr" rid="ref12">Duerkop et al., 2016</xref>). Briefly, 2&#x2009;mL of hospital sewage was centrifuged at 10,000&#x2009;&#x00D7;&#x2009;g for 2&#x2009;min, and the resulting supernatant was filtered through a 0.22&#x2009;&#x03BC;m filter. The filtrate was mixed with log-phase bacteria EFS01 and cultured overnight with shaking at 37&#x00B0;C. The mixture was then centrifuged and filtered using a 0.22&#x2009;&#x03BC;m aseptic filter. Next, 10&#x2009;&#x03BC;L of the resulting supernatant was mixed with 100&#x2009;&#x03BC;L of EFS01 host bacteria and added to 5&#x2009;mL semi-solid BHI before being poured onto agar plates. The plates were then incubated overnight at 37&#x00B0;C until plaques formed. A single plaque was selected and purified by performing the plaque assay three times.</p>
</sec>
<sec id="sec5">
<title>Host range of SFQ1</title>
<p>To determine the host range of SFQ1, the double-layer agar method was conducted on a panel of clinically isolated <italic>E. faecalis</italic> and <italic>E. faecium</italic> strains (<xref rid="tab1" ref-type="table">Table 1</xref>). The strains were grown in BHI medium and their susceptibility to lysis by SFQ1 was determined by the formation of clear plaques. The appearance of clear single plaques indicated sensitivity to the phage and the ability of SFQ1 to lyse the strain.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>The host range of phage SFQ1.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Strain</th>
<th align="left" valign="top">Origin</th>
<th align="center" valign="top">Phage sensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS01</td>
<td align="left" valign="top">Sputum</td>
<td align="center" valign="top">+</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS02</td>
<td align="left" valign="top">Sputum</td>
<td align="center" valign="top">+</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS03</td>
<td align="left" valign="top">Sputum</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS04</td>
<td align="left" valign="top">Sputum</td>
<td align="center" valign="top">+</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS05</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">+</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS06</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS07</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS08</td>
<td align="left" valign="top">Blood</td>
<td align="center" valign="top">+</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS09</td>
<td align="left" valign="top">Blood</td>
<td align="center" valign="top">+</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecalis</italic> EFS10</td>
<td align="left" valign="top">Blood</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecium</italic> EFM01</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecium</italic> EFM02</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecium</italic> EFM03</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecium</italic> EFM04</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
<tr>
<td align="left" valign="top"><italic>E. faecium</italic> EFM05</td>
<td align="left" valign="top">Urine</td>
<td align="center" valign="top">&#x2212;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>&#x201C;+&#x201D; indicates that the strain is sensitive to phage SFQ1, and &#x201C;&#x2212;&#x201D; indicates that phage SFQ1 did not form any plaque on the strain.</p>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec6">
<title>Transmission electron microscopy</title>
<p>Phage SFQ1 morphology was characterized by transmission electron microscopy (TEM) following previously established protocols (<xref ref-type="bibr" rid="ref9">Chatterjee et al., 2019</xref>). In brief, the filtered phage lysate was loaded onto a copper grid and incubated for 10&#x2009;min. The grid was then negatively stained with 10&#x2009;&#x03BC;L of 2% phosphotungstic acid for an additional 5&#x2009;min. After air-drying, the samples were visualized using a transmission electron microscope operating at 80&#x2009;kV.</p>
</sec>
<sec id="sec7">
<title>The optimal MOI of phage</title>
<p>To determine the optimal ratio of bacteriophages to bacteria that could produce the highest yield of progeny, the multiplicity of infection (MOI) needs to be determined. In this study, we investigated the optimal MOI for phage SFQ1 by mixing the phage and host bacteria at MOIs of 0.001, 0.01, 0.1, 1 and 10. The mixture was incubated at 37&#x00B0;C with shaking at 220&#x2009;rpm for 5&#x2009;h. The lysate was then filtered using a 0.45&#x2009;&#x03BC;m filter, and the phage titer in each experiment was determined using the double-layer agar method. The experiment was repeated three times to ensure accuracy.</p>
</sec>
<sec id="sec8">
<title>One-step growth curve</title>
<p>The one-step phage growth process was conducted following the previously described method with some modifications. Initially, 5&#x2009;mL of <italic>E. faecalis</italic> EFS01 in the exponential growth phase was mixed with phage SFQ1 at an MOI of 0.01. After 5&#x2009;min of incubation, the mixtures were diluted by 200 times. The culture was further incubated at 37&#x00B0;C, and samples were collected at 10&#x2009;min intervals. The phage titers in each sample were determined using the double-layer agar method.</p>
</sec>
<sec id="sec9">
<title>Stability of phage SFQ1</title>
<p>The stability of phage SFQ1 was evaluated using various assays. Firstly, pH sensitivity was tested by mixing 10&#x2009;&#x03BC;L of concentrated phage stock solution (2&#x2009;&#x00D7;&#x2009;10<sup>10</sup> PFU/mL) with 990&#x2009;&#x03BC;L of BHI medium, adjusted with HCl or NaOH to pH values ranging from 2.0 to 13.0. The mixture was then incubated at 37&#x00B0;C for 60&#x2009;min, and the phage titer was determined using the double agar layer method. The thermal stability of phage SFQ1 was tested by incubating the phage at temperatures ranging from 4&#x00B0;C to 70&#x00B0;C for 1&#x2009;h, followed by determining the survival phage titer using the double-layer agar method. Additionally, the chloroform sensitivity assay was conducted by incubating phage SFQ1 (10<sup>8</sup> PFU/mL) with varying ratios of chloroform (10%, 30%, 50%, 70%, 90%) at 37&#x00B0;C with shaking for 10&#x2009;min. The mixture was then centrifuged, and the phage titer in the upper layer was calculated using the double-layer agar method.</p>
</sec>
<sec id="sec10">
<title>Phage genome extraction</title>
<p>Extraction of the phage SFQ1 genome was conducted following a previously described method (<xref ref-type="bibr" rid="ref18">Han et al., 2022</xref>). Initially, DNase I and RNase A were added to the phage stocks to attain a final concentration of 1&#x2009;&#x03BC;g/mL, which facilitated the removal of contaminated DNA and RNA. The mixture was then incubated at 37&#x00B0;C for 60&#x2009;min. Subsequently, the phage genomic DNA was extracted using the phenol and chloroform method (<xref ref-type="bibr" rid="ref12">Duerkop et al., 2016</xref>). The DNA was finally dissolved in sterile water and preserved at a temperature of &#x2212;20&#x00B0;C until genome sequencing.</p>
</sec>
<sec id="sec11">
<title>Phage genome sequencing</title>
<p>The genome of phage SFQ1 was sequenced using the Illumina Hiseq 2500 platform. The reads were processed using Fastp to remove any errors and trimmed for quality control. Then, CLC software from QIAGEN (Germany) was applied to assemble the phage genome and annotated with RAST (<xref ref-type="bibr" rid="ref27">Overbeek et al., 2014</xref>), an online tool that predicted the open reading frames (ORFs). Each ORF&#x2019;s DNA and protein sequences were manually searched for homologs by BlastN and BlastP. Finally, the phage genome was visualized using the GraphPad Prism 8.0.2, and the sequence was deposited in NCBI under accession number OQ831052. The antibiotic resistance genes were predicted by the online prediction platform ResFinder<xref rid="fn0003" ref-type="fn">
<sup>1</sup></xref> and the virulence factors were predicted using the VirulenceFinder,<xref rid="fn0004" ref-type="fn">
<sup>2</sup></xref> respectively.</p>
</sec>
<sec id="sec12">
<title>Phylogenetic and comparative analysis of phage genome</title>
<p>To investigate the genetic relationships between phage SFQ1 and other <italic>E. faecalis</italic> phages, a phylogenetic tree was constructed using complete genome sequences of 21 phages, including SFQ1. The analysis was carried out with MEGA 7 software, which allowed for the assessment of similarities and differences in their genetic traits. Additionally, intergenomic similarities between SFQ1 and other <italic>E. faecalis</italic> phages were calculated using VIRIDIC (<xref ref-type="bibr" rid="ref26">Moraru et al., 2020</xref>) to gain a deeper understanding of their relationships.</p>
</sec>
<sec id="sec13">
<title>Biofilm assays</title>
<p>The methodology for the biofilm assay was adapted from a previous study (<xref ref-type="bibr" rid="ref16">Goodarzi et al., 2022</xref>). To establish a biofilm, fill each well of a 96-well plate with 100&#x2009;&#x03BC;L of BHI medium containing an overnight culture of <italic>E. faecalis</italic>. The plates were incubated at 37&#x00B0;C for 24&#x2009;h, 48&#x2009;h, or 72&#x2009;h to allow the biofilm to form. After removing the planktonic cells, 100&#x2009;&#x03BC;L of phage with a titer of 10<sup>8</sup> PFU/mL was added to each well, while control wells were added with 100&#x2009;&#x03BC;L of SM buffer. Incubation was continued at 37&#x00B0;C for 6&#x2009;h. Then, plates were washed with PBS and the biofilm biomass was stained with crystal violet for 15&#x2009;min. To quantify the results, crystal violet was solubilized in 0.2&#x2009;mL of 95% ethanol, and the OD<sub>600</sub> was determined using a SpectraMax M3 multimode microplate reader. Each sample was examined in triplicate, and BHI medium alone served as the negative control.</p>
</sec>
<sec id="sec14">
<title>Statistical analysis</title>
<p>Each experiment was repeated three times to ensure the reliability of the results. The statistical analysis was carried out using GraphPad Prism 8.0.2, and student&#x2019;s <italic>t</italic>-test was used where applicable. A <italic>p</italic>-value less than 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec15" sec-type="results">
<title>Results</title>
<sec id="sec16">
<title>Isolation of <italic>Enterococcus faecalis</italic> bacteriophage SFQ1</title>
<p>Bacteriophage that specifically targets <italic>E. faecalis</italic> strain EFS01 was obtained from the sewage of the hospital. Phage plaques were first observed on a top agar lawn containing the clinical strain EFS01. The plaque was purified three times, resulting in the isolation of phage SFQ1. This phage formed clear plaques that were approximately 3&#x2009;mm in diameter on a double-layered agar plate, as shown in <xref rid="fig1" ref-type="fig">Figure 1A</xref>. Electron microscopy revealed that phage SFQ1 had an icosahedral head with a diameter of around 50&#x2009;nm and a long tail (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). Thus, phage SFQ1 is a siphovirus and was designated vB_EFaS_SFQ1.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>The biological characteristics of phage SFQ1. <bold>(A)</bold> The plaques of phage SFQ1 formed on a double-layered agar plate. <bold>(B)</bold> The transmission electron microscopy image displays the morphology of the phage SFQ1, with a scale bar of 50&#x2009;nm. <bold>(C)</bold> Phage SFQ1 is stable over a broad range of pH values from 5 to 11. <bold>(D)</bold> SFQ1 could tolerate 50&#x00B0;C treatment but was completely inactivated at 70&#x00B0;C. <bold>(E)</bold> SFQ1 is completely resistant to chloroform treatment, and its titer is not changed for various concentrations of chloroform treatment.</p>
</caption>
<graphic xlink:href="fmicb-14-1210319-g001.tif"/>
</fig>
</sec>
<sec id="sec17">
<title>Stability of bacteriophage</title>
<p>Phage SFQ1&#x2019;s stability was evaluated under different pH, temperature, and chloroform treatments. The results revealed that SFQ1 remained viable within a pH range of 5 to 11 (<xref rid="fig1" ref-type="fig">Figure 1C</xref>). Additionally, SFQ1 was able to survive at 50&#x00B0;C but rapidly became inactivated at 60&#x00B0;C (<xref rid="fig1" ref-type="fig">Figure 1D</xref>). However, after chloroform treatment, the titer of SFQ1 is not changed using various concentrations of chloroform, indicating that it is completely resistant to chloroform (<xref rid="fig1" ref-type="fig">Figure 1E</xref>). These findings suggest that SFQ1 can withstand moderate acid and alkali conditions, high temperatures, and chloroform treatment.</p>
</sec>
<sec id="sec18">
<title>Biological characterization of bacteriophage</title>
<p>The optimal MOI was determined by mixing phage with bacteria at different ratios, and when the MOI was 0.01, it produced the maximum titer of particles (1.44&#x2009;&#x00D7;&#x2009;10<sup>10</sup> PFU/mL), indicating that 0.01 is the optimal MOI of SFQ1 (<xref rid="fig2" ref-type="fig">Figure 2A</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p><bold>(A)</bold> The multiplicity of infection assay indicates that SFQ1 produced the most progenies when the phage and host bacteria were mixed at MOIs of 0.01. <bold>(B)</bold> The one-step growth curve for bacteriophage SFQ1 indicates that the phage titer increased after 10&#x2009;min of infection and plateaued at 30&#x2009;min, with a lysis time of approximately 30&#x2009;min.</p>
</caption>
<graphic xlink:href="fmicb-14-1210319-g002.tif"/>
</fig>
<p>To further characterized phage SFQ1, a one-step growth curve experiment was conducted, which showed that phage SFQ1 had a 10&#x2009;min latent period and plateaued 30&#x2009;min after phage infection (<xref rid="fig2" ref-type="fig">Figure 2B</xref>). Thus, the phage lysis time is about 30&#x2009;min, and the burst size is about 110 PFU/cell based on the curve.</p>
<p>The host range of SFQ1 was estimated by plaque assays. Ten clinically isolated <italic>E. faecalis</italic> strains and five <italic>E. faecium</italic> strains were tested for their sensitivity against SFQ1. Six <italic>E. faecalis</italic> strains could be lysed by SFQ1, indicating a modest host range, while none of the <italic>E. faecium</italic> strains could be infected by SFQ1 (<xref rid="tab1" ref-type="table">Table 1</xref>).</p>
</sec>
<sec id="sec19">
<title>Genomic characterization of phage SFQ1</title>
<p>The genome structure of SFQ1, a newly isolated <italic>E. faecalis</italic> phage, was investigated in this study. The phage genome was shown to be linear double-stranded DNA with a length of 40,787 base pairs and a G&#x2009;+&#x2009;C content of 35%. The genomic similarity of SFQ1 to <italic>E. faecalis</italic> Phage (NC_042126.1) was found to be 94.2%, based on sequence alignment. The SFQ1 genome encodes 63 predicted open reading frames (ORFs), with 17 of them considered functional genes and the remaining 46 annotated as hypothetical proteins (<xref rid="fig3" ref-type="fig">Figure 3</xref>). The complete genome sequence of SFQ1 is available at GenBank (accession no. OQ831052).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>The genome characterization of phage SFQ1. The circular genome map of SFQ1 was generated using GraphPad Prism 8.0.2, and the annotation of ORFs was performed using RAST and the BLASTP database. The function of each predicted ORFs of phage SFQ1 are shown, and 17 out of the 63 predicted ORFs are functionally annotated.</p>
</caption>
<graphic xlink:href="fmicb-14-1210319-g003.tif"/>
</fig>
<p>The annotated genes in SFQ1&#x2019;s genome were genes involved in DNA replication and modification, phage genome packaging, structural proteins, and host lysis proteins modules. ORF2 was predicted to encode the HNH homing endonuclease, which is involved in phage DNA packing by cooperation with terminase, which is encoded by ORF3 and ORF4. While the phage structural proteins, such as tail fiber and capsid, are encoded in a specific region. ORF13 encodes the phage major tail protein, ORF15 encodes the phage tail tape measure protein, ORF17 encodes the phage tail assembly protein. The phage lysin, which includes a N-acetylmuramoyl-L-alanine amidase, is also predicted close to the tail fiber gene. But, most of the genes are unknown proteins, such as the genes that are used to control host metabolism are not annotated. And none of the ORFs encoded virulence factors or antibiotic resistance genes, and the genome of SFQ1 did not encode lysogenic modules, such as integrase or repressor proteins. These data indicate that SFQ1 is a strictly lytic phage and can be safely used to treat <italic>E. faecalis</italic> infections.</p>
</sec>
<sec id="sec20">
<title>Phylogenetic analysis</title>
<p>To better understand the evolution and relationship of phage SFQ1 with other <italic>E. faecalis</italic> phages, the genome of SFQ1 was compared with that of 20 <italic>E. faecalis</italic> phages, which were downloaded from NCBI that have homology with SFQ1.</p>
<p>Based on the whole genome sequences, the phylogenetic tree showed that IME278 was grouped into a clade with siphovirus, which is consistent with the results of the whole genome similarity analysis (<xref rid="fig4" ref-type="fig">Figure 4</xref>). Phage vB_EfaS_AL3 was highly similar to phage SFQ1. Then, we used VIRIDIC to calculate the intergenomic similarities, showing the similarity between phages SFQ1 and NC_042126.1 was 84.2%, while that with NC_042023.1 was 80.1% (<xref rid="fig5" ref-type="fig">Figure 5</xref>).</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Phylogenetic analysis of SFQ1 and various <italic>E. faecalis</italic> bacteriophages based on the similarity of the whole genome sequences. SFQ1 was labeled in red in a clade with phage vB_EfaS_AL3.</p>
</caption>
<graphic xlink:href="fmicb-14-1210319-g004.tif"/>
</fig>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Heatmap of the average nucleotide identity values between SFQ1 and 20 most similar bacteriophages. According to a matrix of Hadamard values of pairwise alignment coverage and the percentage identity, the ANI values were generated and SFQ1 was marked in red.</p>
</caption>
<graphic xlink:href="fmicb-14-1210319-g005.tif"/>
</fig>
</sec>
<sec id="sec21">
<title>Biofilm disruption</title>
<p>The efficiency of phage SFQ1 in destroying existing biofilms of <italic>E. faecalis</italic> EFS01 was assessed under various biofilm-forming conditions (<xref rid="fig6" ref-type="fig">Figure 6</xref>). Biofilm experiments were conducted thrice with duplicate readings, and the biofilm was grown to three-time points of 24&#x2009;h, 48&#x2009;h, and 72&#x2009;h. At each stage, phage SFQ1 significantly reduced the <italic>E. faecalis</italic> EFS01 biofilm within 6&#x2009;h, and the reduction was statistically significant (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05) (<xref rid="fig6" ref-type="fig">Figure 6</xref>), indicating that SFQ1 can disrupt the biofilm efficiently.</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption>
<p>The effect of phage SFQ1 on biofilms formed by <italic>E. faecalis</italic> EFS01 was evaluated by measuring biofilm using crystal violet assay before and after phage treatment. Biofilms were formed for 24&#x2009;h, 48&#x2009;h, or 72&#x2009;h, and were treated with phage SFQ1 for 6&#x2009;h. The results showed that phage SFQ1 had a significant effect on biofilms formed for all three-time points. The asterisks indicate statistical significance (<italic>p</italic>&#x2009;&#x003C;&#x2009;0.05).</p>
</caption>
<graphic xlink:href="fmicb-14-1210319-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="sec22" sec-type="discussions">
<title>Discussion</title>
<p>Phage therapy has been widely recognized as a promising strategy for treating infectious diseases caused by various bacteria, including <italic>E. faecalis</italic> (<xref ref-type="bibr" rid="ref14">El Haddad et al., 2019</xref>). Thus, more and more <italic>E. faecalis</italic> phages were identified that targets different parts of the <italic>E. faecalis</italic> cell wall, and the cocktail with different phages could reduce the likelihood of phage resistance development (<xref ref-type="bibr" rid="ref4">Banla et al., 2018</xref>; <xref ref-type="bibr" rid="ref2">Al-Zubidi et al., 2019</xref>; <xref ref-type="bibr" rid="ref9">Chatterjee et al., 2019</xref>). One study identified a cocktail of phages that were effective in killing antibiotic-resistant <italic>E. faecalis</italic> strains <italic>in vitro</italic> but not effective in the gut of mice (<xref ref-type="bibr" rid="ref7">Buttimer et al., 2022</xref>). In addition to the well-known phage therapy, phages also play a vital role in treating many other diseases. For instance, (<xref ref-type="bibr" rid="ref11">Duan et al., 2019</xref>) discovered phages that specifically target cytolysin-positive <italic>E. faecalis</italic> strains, which can cause hepatocyte lysis under the alcohol condition and lead to alcoholic hepatitis. The use of these phages has shown promising results in treating alcoholic hepatitis caused by <italic>E. faecalis.</italic> The development of phages with specificity against different <italic>E. faecalis</italic> strains has the potential to revolutionize the treatment of infectious diseases caused by this bacterium. Moreover, the characterization of <italic>E. faecalis</italic> phages can also shed light on their potential role in the gut microbiome and provide new therapeutic opportunities for gut microbiome-associated diseases. Therefore, further research and characterization of <italic>E. faecalis</italic> phages are essential for developing effective therapies against <italic>E. faecalis</italic> infections and other microbiome-associated diseases.</p>
<p>In this study, we characterized an effective <italic>E. faecalis</italic> phage SFQ1, it is a dsDNA phage with a large burst size, and lyse the host effectively. Moreover, its genome was sequenced and did not encode any lysogenic gene, antibiotic resistance gene, or virulent gene. Thus, SFQ1 is an effective and safe candidate for phage therapy.</p>
<p>Biofilms are communities of bacteria that can be highly resistant to antibiotics and can contribute to persistent infections (<xref ref-type="bibr" rid="ref23">Khalifa et al., 2015</xref>; <xref ref-type="bibr" rid="ref30">Sanz et al., 2017</xref>). Thus, researchers have investigated the potential of using phages to treat biofilm-related <italic>E. faecalis</italic> infections. A study found that a phage cocktail was effective in reducing <italic>E. faecalis</italic> biofilm formation <italic>in vitro</italic>, suggesting its potential use as a therapeutic agent (<xref ref-type="bibr" rid="ref23">Khalifa et al., 2015</xref>). In this study, we also test the effect of SFQ1 on disrupting the existing biofilm, and we found that all three stage biofilms could be significantly disrupted by phage SFQ1, thus in clinical therapy, SFQ1 could be effective when combined with the use of antibiotics.</p>
<p>In conclusion, our findings highlight the potential of SFQ1 as a promising candidate for phage therapy against <italic>E. faecalis</italic> infections. Future studies should focus on identifying its specific receptor, which is critical for developing effective phage cocktails and minimizing the risk of phage resistance. Overall, this study suggested the importance of exploring the potential of phages as alternative therapies against antibiotic-resistant bacteria.</p>
</sec>
<sec id="sec23" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.</p>
</sec>
<sec id="sec24">
<title>Author contributions</title>
<p>WG and XW conceived and designed the experiments. FS, JS, JT, and HX performed the experiments. FS and JS analyzed the data. WG and XW wrote the paper. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="sec25" sec-type="funding-information">
<title>Funding</title>
<p>This research was supported by Natural Science Foundation of Sichuan Province of China (2023NSFSC1902).</p>
</sec>
<sec id="conf1" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="ref1">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname> <given-names>I. A. A.</given-names></name> <name><surname>Neelakantan</surname> <given-names>P.</given-names></name></person-group> (<year>2022</year>). <article-title>Antibiofilm activity of phytochemicals against <italic>Enterococcus faecalis</italic>: a literature review</article-title>. <source>Phytother. Res.</source> <volume>36</volume>, <fpage>2824</fpage>&#x2013;<lpage>2838</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ptr.7488</pub-id>, PMID: <pub-id pub-id-type="pmid">35522168</pub-id></citation>
</ref>
<ref id="ref2">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Zubidi</surname> <given-names>M.</given-names></name> <name><surname>Widziolek</surname> <given-names>M.</given-names></name> <name><surname>Court</surname> <given-names>E. K.</given-names></name> <name><surname>Gains</surname> <given-names>A. F.</given-names></name> <name><surname>Smith</surname> <given-names>R. E.</given-names></name> <name><surname>Ansbro</surname> <given-names>K.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Identification of novel bacteriophages with therapeutic potential that target <italic>Enterococcus faecalis</italic></article-title>. <source>Infect. Immun.</source> <volume>87</volume>:<fpage>e00512</fpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00512-19</pub-id>, PMID: <pub-id pub-id-type="pmid">31451618</pub-id></citation>
</ref>
<ref id="ref3">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arias</surname> <given-names>C. A.</given-names></name> <name><surname>Panesso</surname> <given-names>D.</given-names></name> <name><surname>McGrath</surname> <given-names>D. M.</given-names></name> <name><surname>Qin</surname> <given-names>X.</given-names></name> <name><surname>Mojica</surname> <given-names>M. F.</given-names></name> <name><surname>Miller</surname> <given-names>C.</given-names></name> <etal/></person-group>. (<year>2011</year>). <article-title>Genetic basis for <italic>in vivo</italic> daptomycin resistance in enterococci</article-title>. <source>N. Engl. J. Med.</source> <volume>365</volume>, <fpage>892</fpage>&#x2013;<lpage>900</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1011138</pub-id>, PMID: <pub-id pub-id-type="pmid">21899450</pub-id></citation>
</ref>
<ref id="ref4">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banla</surname> <given-names>I. L.</given-names></name> <name><surname>Kommineni</surname> <given-names>S.</given-names></name> <name><surname>Hayward</surname> <given-names>M.</given-names></name> <name><surname>Rodrigues</surname> <given-names>M.</given-names></name> <name><surname>Palmer</surname> <given-names>K. L.</given-names></name> <name><surname>Salzman</surname> <given-names>N. H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Modulators of <italic>Enterococcus faecalis</italic> cell envelope integrity and antimicrobial resistance influence stable colonization of the mammalian gastrointestinal tract</article-title>. <source>Infect. Immun.</source> <volume>86</volume>:<fpage>e00381</fpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00381-17</pub-id>, PMID: <pub-id pub-id-type="pmid">29038125</pub-id></citation>
</ref>
<ref id="ref5">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname> <given-names>J.</given-names></name> <name><surname>Wu</surname> <given-names>N.</given-names></name> <name><surname>Zeng</surname> <given-names>Y.</given-names></name> <name><surname>Chen</surname> <given-names>L.</given-names></name> <name><surname>Li</surname> <given-names>L.</given-names></name> <name><surname>Yang</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant <italic>Klebsiella pneumoniae</italic></article-title>. <source>Emerg. Microbes. Infect.</source> <volume>9</volume>, <fpage>771</fpage>&#x2013;<lpage>774</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2020.1747950</pub-id>, PMID: <pub-id pub-id-type="pmid">32212918</pub-id></citation>
</ref>
<ref id="ref6">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bright</surname> <given-names>M.</given-names></name> <name><surname>Parfitt</surname> <given-names>E. C.</given-names></name> <name><surname>Pasquill</surname> <given-names>K.</given-names></name> <name><surname>Steele</surname> <given-names>L.</given-names></name> <name><surname>Laupland</surname> <given-names>K. B.</given-names></name></person-group> (<year>2020</year>). <article-title>Occurrence and determinants of enterococcal bloodstream infections: a population-based study</article-title>. <source>Infect. Dis.</source> <volume>52</volume>, <fpage>638</fpage>&#x2013;<lpage>643</lpage>. doi: <pub-id pub-id-type="doi">10.1080/23744235.2020.1774074</pub-id>, PMID: <pub-id pub-id-type="pmid">32516011</pub-id></citation>
</ref>
<ref id="ref7">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buttimer</surname> <given-names>C.</given-names></name> <name><surname>Sutton</surname> <given-names>T.</given-names></name> <name><surname>Colom</surname> <given-names>J.</given-names></name> <name><surname>Murray</surname> <given-names>E.</given-names></name> <name><surname>Bettio</surname> <given-names>P. H.</given-names></name> <name><surname>Smith</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Impact of a phage cocktail targeting <italic>Escherichia coli</italic> and <italic>Enterococcus faecalis</italic> as members of a gut bacterial consortium in vitro and in vivo</article-title>. <source>Front. Microbiol.</source> <volume>13</volume>:<fpage>936083</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2022.936083</pub-id>, PMID: <pub-id pub-id-type="pmid">35935217</pub-id></citation>
</ref>
<ref id="ref8">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cattoir</surname> <given-names>V.</given-names></name>
</person-group> (<year>2022</year>). <article-title>The multifaceted lifestyle of enterococci: genetic diversity, ecology and risks for public health</article-title>. <source>Curr. Opin. Microbiol.</source> <volume>65</volume>, <fpage>73</fpage>&#x2013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.mib.2021.10.013</pub-id>, PMID: <pub-id pub-id-type="pmid">34768106</pub-id></citation>
</ref>
<ref id="ref9">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname> <given-names>A.</given-names></name> <name><surname>Johnson</surname> <given-names>C. N.</given-names></name> <name><surname>Luong</surname> <given-names>P.</given-names></name> <name><surname>Hullahalli</surname> <given-names>K.</given-names></name> <name><surname>McBride</surname> <given-names>S. W.</given-names></name> <name><surname>Schubert</surname> <given-names>A. M.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Bacteriophage resistance alters antibiotic-mediated intestinal expansion of enterococci</article-title>. <source>Infect. Immun.</source> <volume>87</volume>:<fpage>e00085</fpage>. doi: <pub-id pub-id-type="doi">10.1128/IAI.00085-19</pub-id>, PMID: <pub-id pub-id-type="pmid">30936157</pub-id></citation>
</ref>
<ref id="ref10">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dion</surname> <given-names>M. B.</given-names></name> <name><surname>Oechslin</surname> <given-names>F.</given-names></name> <name><surname>Moineau</surname> <given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>Phage diversity, genomics and phylogeny</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>18</volume>, <fpage>125</fpage>&#x2013;<lpage>138</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-019-0311-5</pub-id></citation>
</ref>
<ref id="ref11">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname> <given-names>Y.</given-names></name> <name><surname>Llorente</surname> <given-names>C.</given-names></name> <name><surname>Lang</surname> <given-names>S.</given-names></name> <name><surname>Brandl</surname> <given-names>K.</given-names></name> <name><surname>Chu</surname> <given-names>H.</given-names></name> <name><surname>Jiang</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease</article-title>. <source>Nature</source> <volume>575</volume>, <fpage>505</fpage>&#x2013;<lpage>511</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-019-1742-x</pub-id>, PMID: <pub-id pub-id-type="pmid">31723265</pub-id></citation>
</ref>
<ref id="ref12">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duerkop</surname> <given-names>B. A.</given-names></name> <name><surname>Huo</surname> <given-names>W.</given-names></name> <name><surname>Bhardwaj</surname> <given-names>P.</given-names></name> <name><surname>Palmer</surname> <given-names>K. L.</given-names></name> <name><surname>Hooper</surname> <given-names>L. V.</given-names></name></person-group> (<year>2016</year>). <article-title>Molecular basis for lytic bacteriophage resistance in enterococci</article-title>. <source>mBio</source> <volume>7</volume>:<fpage>e01304</fpage>. doi: <pub-id pub-id-type="doi">10.1128/mBio.01304-16</pub-id>, PMID: <pub-id pub-id-type="pmid">27578757</pub-id></citation>
</ref>
<ref id="ref13">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egido</surname> <given-names>J. E.</given-names></name> <name><surname>Costa</surname> <given-names>A. R.</given-names></name> <name><surname>Aparicio-Maldonado</surname> <given-names>C.</given-names></name> <name><surname>Haas</surname> <given-names>P. J.</given-names></name> <name><surname>Brouns</surname> <given-names>S. J. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Mechanisms and clinical importance of bacteriophage resistance</article-title>. <source>FEMS Microbiol. Rev.</source> <volume>46</volume>:<fpage>fuab048</fpage>. doi: <pub-id pub-id-type="doi">10.1093/femsre/fuab048</pub-id></citation>
</ref>
<ref id="ref14">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>El Haddad</surname> <given-names>L.</given-names></name> <name><surname>Harb</surname> <given-names>C. P.</given-names></name> <name><surname>Gebara</surname> <given-names>M. A.</given-names></name> <name><surname>Stibich</surname> <given-names>M. A.</given-names></name> <name><surname>Chemaly</surname> <given-names>R. F.</given-names></name></person-group> (<year>2019</year>). <article-title>A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans</article-title>. <source>Clin. Infect. Dis.</source> <volume>69</volume>, <fpage>167</fpage>&#x2013;<lpage>178</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/ciy947</pub-id>, PMID: <pub-id pub-id-type="pmid">30395179</pub-id></citation>
</ref>
<ref id="ref15">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelman</surname> <given-names>D.</given-names></name> <name><surname>Yerushalmy</surname> <given-names>O.</given-names></name> <name><surname>Alkalay-Oren</surname> <given-names>S.</given-names></name> <name><surname>Rakov</surname> <given-names>C.</given-names></name> <name><surname>Ben-Porat</surname> <given-names>S.</given-names></name> <name><surname>Khalifa</surname> <given-names>L.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Clinical phage microbiology: a suggested framework and recommendations for the <italic>in-vitro</italic> matching steps of phage therapy</article-title>. <source>Lancet Microbe.</source> <volume>2</volume>, <fpage>e555</fpage>&#x2013;<lpage>e563</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2666-5247(21)00127-0</pub-id>, PMID: <pub-id pub-id-type="pmid">35544180</pub-id></citation>
</ref>
<ref id="ref16">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goodarzi</surname> <given-names>F.</given-names></name> <name><surname>Hallajzadeh</surname> <given-names>M.</given-names></name> <name><surname>Sholeh</surname> <given-names>M.</given-names></name> <name><surname>Talebi</surname> <given-names>M.</given-names></name> <name><surname>Pirhajati Mahabadi</surname> <given-names>V.</given-names></name> <name><surname>Amirmozafari</surname> <given-names>N.</given-names></name></person-group> (<year>2022</year>). <article-title>Anti-biofilm activity of a lytic phage against vancomycin-resistant <italic>Enterococcus faecalis</italic></article-title>. <source>Iran. J. Pathol.</source> <volume>17</volume>, <fpage>285</fpage>&#x2013;<lpage>294</lpage>. doi: <pub-id pub-id-type="doi">10.30699/ijp.2022.541855.2760</pub-id>, PMID: <pub-id pub-id-type="pmid">36247507</pub-id></citation>
</ref>
<ref id="ref17">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gorski</surname> <given-names>A.</given-names></name> <name><surname>Mi&#x0119;dzybrodzki</surname> <given-names>R.</given-names></name> <name><surname>Weber-D&#x0105;browska</surname> <given-names>B.</given-names></name> <name><surname>Fortuna</surname> <given-names>W.</given-names></name> <name><surname>Letkiewicz</surname> <given-names>S.</given-names></name> <name><surname>Rog&#x00F3;&#x017C;</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases</article-title>. <source>Front. Microbiol.</source> <volume>7</volume>:<fpage>9</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2016.01515</pub-id></citation>
</ref>
<ref id="ref18">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>K.</given-names></name> <name><surname>Dong</surname> <given-names>Y.</given-names></name> <name><surname>An</surname> <given-names>X.</given-names></name> <name><surname>Song</surname> <given-names>L.</given-names></name> <name><surname>Li</surname> <given-names>M.</given-names></name> <name><surname>Fan</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Potential application of a newly isolated phage BUCT609 infecting <italic>Stenotrophomonas maltophilia</italic></article-title>. <source>Front. Microbiol.</source> <volume>13</volume>:<fpage>1001237</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2022.1001237</pub-id>, PMID: <pub-id pub-id-type="pmid">36478859</pub-id></citation>
</ref>
<ref id="ref19">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname> <given-names>K.</given-names></name> <name><surname>Marchaim</surname> <given-names>D.</given-names></name> <name><surname>Palla</surname> <given-names>M.</given-names></name> <name><surname>Gudur</surname> <given-names>U. M.</given-names></name> <name><surname>Pulluru</surname> <given-names>H.</given-names></name> <name><surname>Bathina</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Epidemiology of vancomycin-resistant <italic>Enterococcus faecalis</italic>: a case-case-control study</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>57</volume>, <fpage>49</fpage>&#x2013;<lpage>55</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.01271-12</pub-id>, PMID: <pub-id pub-id-type="pmid">23070173</pub-id></citation>
</ref>
<ref id="ref20">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jabbari Shiadeh</surname> <given-names>S. M.</given-names></name> <name><surname>Pormohammad</surname> <given-names>A.</given-names></name> <name><surname>Hashemi</surname> <given-names>A.</given-names></name> <name><surname>Lak</surname> <given-names>P.</given-names></name></person-group> (<year>2019</year>). <article-title>Global prevalence of antibiotic resistance in blood-isolated <italic>Enterococcus faecalis</italic> and <italic>Enterococcus faecium</italic>: a systematic review and meta-analysis</article-title>. <source>Infect. Drug Resist.</source> <volume>12</volume>, <fpage>2713</fpage>&#x2013;<lpage>2725</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IDR.S206084</pub-id>, PMID: <pub-id pub-id-type="pmid">31564921</pub-id></citation>
</ref>
<ref id="ref21">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jault</surname> <given-names>P.</given-names></name> <name><surname>Leclerc</surname> <given-names>T.</given-names></name> <name><surname>Jennes</surname> <given-names>S.</given-names></name> <name><surname>Pirnay</surname> <given-names>J. P.</given-names></name> <name><surname>Que</surname> <given-names>Y. A.</given-names></name> <name><surname>Resch</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by <italic>Pseudomonas aeruginosa</italic> (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial</article-title>. <source>Lancet Infect. Dis.</source> <volume>19</volume>, <fpage>35</fpage>&#x2013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(18)30482-1</pub-id></citation>
</ref>
<ref id="ref22">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kakoullis</surname> <given-names>L.</given-names></name> <name><surname>Papachristodoulou</surname> <given-names>E.</given-names></name> <name><surname>Chra</surname> <given-names>P.</given-names></name> <name><surname>Panos</surname> <given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Mechanisms of antibiotic resistance in important gram-positive and gram-negative pathogens and novel antibiotic solutions</article-title>. <source>Antibiotics</source> <volume>10</volume>:<fpage>415</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antibiotics10040415</pub-id></citation>
</ref>
<ref id="ref23">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khalifa</surname> <given-names>L.</given-names></name> <name><surname>Brosh</surname> <given-names>Y.</given-names></name> <name><surname>Gelman</surname> <given-names>D.</given-names></name> <name><surname>Coppenhagen-Glazer</surname> <given-names>S.</given-names></name> <name><surname>Beyth</surname> <given-names>S.</given-names></name> <name><surname>Poradosu-Cohen</surname> <given-names>R.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Targeting <italic>Enterococcus faecalis</italic> biofilms with phage therapy</article-title>. <source>Appl. Environ. Microbiol.</source> <volume>81</volume>, <fpage>2696</fpage>&#x2013;<lpage>2705</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AEM.00096-15</pub-id>, PMID: <pub-id pub-id-type="pmid">25662974</pub-id></citation>
</ref>
<ref id="ref24">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leitner</surname> <given-names>L.</given-names></name> <name><surname>Ujmajuridze</surname> <given-names>A.</given-names></name> <name><surname>Chanishvili</surname> <given-names>N.</given-names></name> <name><surname>Goderdzishvili</surname> <given-names>M.</given-names></name> <name><surname>Chkonia</surname> <given-names>I.</given-names></name> <name><surname>Rigvava</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial</article-title>. <source>Lancet Infect. Dis.</source> <volume>21</volume>, <fpage>427</fpage>&#x2013;<lpage>436</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30330-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32949500</pub-id></citation>
</ref>
<ref id="ref25">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luong</surname> <given-names>T.</given-names></name> <name><surname>Salabarria</surname> <given-names>A. C.</given-names></name> <name><surname>Edwards</surname> <given-names>R. A.</given-names></name> <name><surname>Roach</surname> <given-names>D. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Standardized bacteriophage purification for personalized phage therapy</article-title>. <source>Nat. Protoc.</source> <volume>15</volume>, <fpage>2867</fpage>&#x2013;<lpage>2890</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41596-020-0346-0</pub-id>, PMID: <pub-id pub-id-type="pmid">32709990</pub-id></citation>
</ref>
<ref id="ref26">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moraru</surname> <given-names>C.</given-names></name> <name><surname>Varsani</surname> <given-names>A.</given-names></name> <name><surname>Kropinski</surname> <given-names>A. M.</given-names></name></person-group> (<year>2020</year>). <article-title>VIRIDIC-A novel tool to calculate the Intergenomic similarities of prokaryote-infecting viruses</article-title>. <source>Viruses</source> <volume>12</volume>:<fpage>1268</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v12111268</pub-id></citation>
</ref>
<ref id="ref27">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overbeek</surname> <given-names>R.</given-names></name> <name><surname>Olson</surname> <given-names>R.</given-names></name> <name><surname>Pusch</surname> <given-names>G. D.</given-names></name> <name><surname>Olsen</surname> <given-names>G. J.</given-names></name> <name><surname>Davis</surname> <given-names>J. J.</given-names></name> <name><surname>Disz</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>The SEED and the rapid annotation of microbial genomes using subsystems technology (RAST)</article-title>. <source>Nucleic Acids Res.</source> <volume>42</volume>, <fpage>D206</fpage>&#x2013;<lpage>D214</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkt1226</pub-id>, PMID: <pub-id pub-id-type="pmid">24293654</pub-id></citation>
</ref>
<ref id="ref28">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pires</surname> <given-names>D. P.</given-names></name> <name><surname>Costa</surname> <given-names>A. R.</given-names></name> <name><surname>Pinto</surname> <given-names>G.</given-names></name> <name><surname>Meneses</surname> <given-names>L.</given-names></name> <name><surname>Azeredo</surname> <given-names>J.</given-names></name></person-group> (<year>2020</year>). <article-title>Current challenges and future opportunities of phage therapy</article-title>. <source>FEMS Microbiol. Rev.</source> <volume>44</volume>, <fpage>684</fpage>&#x2013;<lpage>700</lpage>. doi: <pub-id pub-id-type="doi">10.1093/femsre/fuaa017</pub-id>, PMID: <pub-id pub-id-type="pmid">32472938</pub-id></citation>
</ref>
<ref id="ref29">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pires</surname> <given-names>D. P.</given-names></name> <name><surname>Vilas Boas</surname> <given-names>D.</given-names></name> <name><surname>Sillankorva</surname> <given-names>S.</given-names></name> <name><surname>Azeredo</surname> <given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Phage therapy: a step forward in the treatment of <italic>Pseudomonas aeruginosa</italic> infections</article-title>. <source>J. Virol.</source> <volume>89</volume>, <fpage>7449</fpage>&#x2013;<lpage>7456</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00385-15</pub-id>, PMID: <pub-id pub-id-type="pmid">25972556</pub-id></citation>
</ref>
<ref id="ref30">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanz</surname> <given-names>M.</given-names></name> <name><surname>Beighton</surname> <given-names>D.</given-names></name> <name><surname>Curtis</surname> <given-names>M. A.</given-names></name> <name><surname>Cury</surname> <given-names>J. A.</given-names></name> <name><surname>Dige</surname> <given-names>I.</given-names></name> <name><surname>Dommisch</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Role of microbial biofilms in the maintenance of oral health and in the development of dental caries and periodontal diseases. Consensus report of group 1 of the joint EFP/ORCA workshop on the boundaries between caries and periodontal disease</article-title>. <source>J. Clin. Periodontol.</source> <volume>44</volume>, <fpage>S5</fpage>&#x2013;<lpage>S11</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jcpe.12682</pub-id>, PMID: <pub-id pub-id-type="pmid">28266109</pub-id></citation>
</ref>
<ref id="ref31">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Strathdee</surname> <given-names>S. A.</given-names></name> <name><surname>Hatfull</surname> <given-names>G. F.</given-names></name> <name><surname>Mutalik</surname> <given-names>V. K.</given-names></name> <name><surname>Schooley</surname> <given-names>R. T.</given-names></name></person-group> (<year>2023</year>). <article-title>Phage therapy: from biological mechanisms to future directions</article-title>. <source>Cells</source> <volume>186</volume>, <fpage>17</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2022.11.017</pub-id>, PMID: <pub-id pub-id-type="pmid">36608652</pub-id></citation>
</ref>
<ref id="ref32">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Theuretzbacher</surname> <given-names>U.</given-names></name> <name><surname>Outterson</surname> <given-names>K.</given-names></name> <name><surname>Engel</surname> <given-names>A.</given-names></name> <name><surname>Karl&#x00E9;n</surname> <given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>The global preclinical antibacterial pipeline</article-title>. <source>Nat. Rev. Microbiol.</source> <volume>18</volume>, <fpage>275</fpage>&#x2013;<lpage>285</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41579-019-0288-0</pub-id>, PMID: <pub-id pub-id-type="pmid">31745331</pub-id></citation>
</ref>
<ref id="ref33">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uyttebroek</surname> <given-names>S.</given-names></name> <name><surname>Chen</surname> <given-names>B.</given-names></name> <name><surname>Onsea</surname> <given-names>J.</given-names></name> <name><surname>Ruythooren</surname> <given-names>F.</given-names></name> <name><surname>Debaveye</surname> <given-names>Y.</given-names></name> <name><surname>Devolder</surname> <given-names>D.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review</article-title>. <source>Lancet Infect. Dis.</source> <volume>22</volume>, <fpage>e208</fpage>&#x2013;<lpage>e220</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00612-5</pub-id>, PMID: <pub-id pub-id-type="pmid">35248167</pub-id></citation>
</ref>
<ref id="ref34">
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Venkateswaran</surname> <given-names>P.</given-names></name> <name><surname>Lakshmanan</surname> <given-names>P. M.</given-names></name> <name><surname>Muthukrishnan</surname> <given-names>S.</given-names></name> <name><surname>Bhagavathi</surname> <given-names>H.</given-names></name> <name><surname>Vasudevan</surname> <given-names>S.</given-names></name> <name><surname>Neelakantan</surname> <given-names>P.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Hidden agenda of <italic>Enterococcus faecalis</italic> lifestyle transition: planktonic to sessile state</article-title>. <source>Future Microbiol.</source> <volume>17</volume>, <fpage>1051</fpage>&#x2013;<lpage>1069</lpage>. doi: <pub-id pub-id-type="doi">10.2217/fmb-2021-0212</pub-id></citation>
</ref>
</ref-list>
<fn-group>
<fn id="fn0003">
<p>
<sup>1</sup>
<ext-link xlink:href="https://cge.cbs.dtu.dk/services/ResFinder/" ext-link-type="uri">https://cge.cbs.dtu.dk/services/ResFinder/</ext-link>
</p>
</fn>
<fn id="fn0004">
<p>
<sup>2</sup>
<ext-link xlink:href="https://cge.cbs.dtu.dk/services/VirulenceFinder/" ext-link-type="uri">https://cge.cbs.dtu.dk/services/VirulenceFinder/</ext-link>
</p>
</fn>
</fn-group>
</back>
</article>